A “breakthrough therapy” user fee might help deter product sponsors from submitting frivolous designation requests with impunity, a cancer expert suggested at the Brookings meeting on the expedited regulatory program April 24.
George Demetri, a professor of medicine at Harvard and senior VP for experimental therapeutics at the Dana-Farber Cancer Institute, said that companies with questionable data might be less inclined to...